Boston's resTORbio Sets Terms for $85M IPO Post author:Sam Post published:January 16, 2018 Post category:BioPharma resTORbio is developing novel therapies to improve immune function in the elderly. Source: BioSpace You Might Also Like Debt-Ridden Teva Considers Cutting Up to 10,000 Jobs December 10, 2017 Xeris Raises $55M for Glucagon Rescue Pen March 8, 2018 Innate Tanked as Drug Combined With Bristol-Myers' Opdivo Flopped in Study November 26, 2017
